Frederick National Laboratory for Cancer Research

Director, Molecular Pharmacology Branch Laboratories

Frederick, MD, USA
Dec 05, 2018
Required Education
Position Type
Full time
The Molecular Pharmacology Branch (MPB) mission is to improve the treatment of recalcitrant, rare and neglected cancers through the identification of potential targets, the screening of new and known agents, the identification of genomic vulnerabilities and the identification of potential therapeutic combinations using state-of-the-art molecular characterization, mechanism-of-action techniques. In support of this mission, the MPB operates four laboratories at the National Cancer Institute-Frederick campus. While the Translational Support Laboratory is a federal laboratory, the other three laboratories are operated by the contractor that holds the Frederick National Laboratory for Cancer Research (FNLCR) contract with the NCI (currently Leidos Biomedical Research, Inc): the NCI60 Screening Laboratory, the In Vitro Screening Laboratory, and the Molecular Pharmacology Laboratory.


The Director will serve as the scientific leader and director for the three contractor operated MPB labs (i.e., the NCI60 screening, Target Validation and Screening, and the Molecular Pharmacology Laboratories) at the Frederick National Laboratory for Cancer Research (FNLCR) as well as the co-investigator of the MPB Branch. The incumbent must have expertise in cancer biology, genomics, molecular pharmacology, and experimental therapeutics.

The successful candidate must have:
  • A strong understanding of cancer research especially drug mechanism(s); be fluent in the use of leading-edge technology of gene manipulation (e.g., deletion and insertion) for drug mechanism of action (MOA) studies; and have strength in cell biology
  • Knowledge of current data storage and analysis methods especially those used for large databases
  • Ability to lead collaborations with computational biologists and statisticians to identify deregulated cellular processes utilizing patient derived models and -omic databases to inform therapeutic choices, development testable mechanistic hypotheses suitable for clinical trial evaluation, and explain differences in drug sensitivity between individual PDX models
  • Ability to guide the design, execution and interpretation of in vitro studies to validate drug targets and to explore the therapeutic potential of these targets; design and develop cell and molecular assays to define the MOA of compounds; and identify drug-induced molecular changes that can be converted into pharmacodynamic endpoints in pre-clinical and clinical studies.

The Director will:
  • Create and implement an integrated and comprehensive laboratory program for investigating key molecular pharmacology questions that closely aligns with the mission of MPB in DCTD/DTP and adds significant translational value
  • Identify important, mission-critical problems in molecular pharmacology to investigate and will design and deliver the scientific investigations to address them
  • Interpret, present, and report research findings at internal, national, and international scientific meetings
  • Publish findings in high impact peer-reviewed journals
  • Manage the activity and performance of direct reports and oversee their supervision of technical staff

  • Possession of a Doctoral degree (e.g., D.V.M., D.Sc., M.D., or Ph.D.) from an accredited college or university according to the Council for Higher Education Accreditation (CHEA) in a related field (Additional qualifying experience may be substituted for the required education). Foreign degrees must be evaluated for U.S. equivalency.
  • A minimum of ten (10) years of post-graduate experience, including at least five (5) years at the Senior Scientist level. Five (5) or more years of experience managing complex laboratory research programs is also required.
  • Must be able to obtain and maintain a clearance

  • Demonstrated ability to develop and implement new research plans for complex projects involving molecular pharmacology strategies that have led to timely and actionable conclusions
  • Demonstrated skills in effective written and oral communication
  • Achievement and experience in the molecular pharmacology of anti-cancer agents; the investigation of their mechanisms of action and interactions, and their evaluation using in vitro systems

Expected Competencies:
  • Established track record of conducting research that has produced first and last authorship, in peer-reviewed publications, with a high citation record
  • Recognized as a scientific leader by peers (e.g., attendance and presentation at national and international meetings, presiding and chairing national and international meetings, receiving invitations for lectureships, establishing scientific meetings or symposium as part of a national or international meeting or symposium or as a separate meeting, etc.)
  • Experience supervising staff including conveying and implementing a vision toward new directions and the mentoring of scientific staff
  • Ability to recognize which leading edge technologies are useful to pursue
  • Ability to collaborate with laboratory and clinical experts at the national and/or international level
Equal Opportunity Employer (EOE) | Minority/Female/Disabled/Veteran (M/F/D/V) | Drug Free Workplace (DFW)